Cargando…
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
BACKGROUND: This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study. METHODS: This randomised...
Autores principales: | Zhu, Feng-Cai, Guan, Xu-Hua, Li, Yu-Hua, Huang, Jian-Ying, Jiang, Tao, Hou, Li-Hua, Li, Jing-Xin, Yang, Bei-Fang, Wang, Ling, Wang, Wen-Juan, Wu, Shi-Po, Wang, Zhao, Wu, Xiao-Hong, Xu, Jun-Jie, Zhang, Zhe, Jia, Si-Yue, Wang, Bu-Sen, Hu, Yi, Liu, Jing-Jing, Zhang, Jun, Qian, Xiao-Ai, Li, Qiong, Pan, Hong-Xing, Jiang, Hu-Dachuan, Deng, Peng, Gou, Jin-Bo, Wang, Xue-Wen, Wang, Xing-Huan, Chen, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836858/ https://www.ncbi.nlm.nih.gov/pubmed/32702299 http://dx.doi.org/10.1016/S0140-6736(20)31605-6 |
Ejemplares similares
-
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
por: Zhu, Feng-Cai, et al.
Publicado: (2020) -
Relationship of Placental and Serum Lipoprotein-Associated Phospholipase A2 Levels with Hypertensive Disorders of Pregnancy
por: Wang, Jing, et al.
Publicado: (2022) -
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
por: Pan, Hong-Xing, et al.
Publicado: (2021) -
Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
por: Zhang, Xuefeng, et al.
Publicado: (2018) -
Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
por: Zhang, Xuefeng, et al.
Publicado: (2018)